{"nct_id":"NCT04134728","title":"Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors","status":"COMPLETED","status_verified_date":"2023-07","start_date":"2019-10-31","start_date_type":"ACTUAL","primary_completion_date":"2021-09-15","primary_completion_date_type":"ACTUAL","completion_date":"2022-02-01","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["GSK"]}